Population
Isolated normal human adult articular chondrocytes, osteoarthritic human articular chondrocytes, neonatal…
Design
Preclinical
Follow-up
Up to 150 days (in vitro) and at least 10 days (in vivo)
Authors
Loading...
Supports rAAV gene delivery in human chondrocytes; leaves open in vivo efficacy and clinical translation for joint disorders.
rAAV vectors can efficiently transduce and stably express foreign genes in normal and osteoarthritic human articular chondrocytes, demonstrating potential for gene therapy in joint disorders.
Madry et al. (2003) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: